Daniel Grosslight

Q: What is Daniel Grosslight's success rate?

Daniel Grosslight currently has a success rate of 88.68696228995138.

Q: What is the average return of Daniel Grosslight's calls?

Their stock ratings have generated an average return of 32.507474050677985.

Citigroup | Healthcare

Daniel Grosslight is an analyst from Citigroup specializing in the Healthcare sector. Ranked #677 out of 4771 analysts, they have issued 63 stock ratings with a success rate of 88.69% and an average return of 32.51%.

Daniel Grosslight has a well-established track record, with 63 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 88.69% and an average return of 32.51%, underscoring their expertise and ability to identify winning opportunities for investors.

#677

Out of 4771

Total Ratings

+88.69%

Success Rate

+32.51%

Average Return

Recent Ratings Analysis

BIO

Hold

Aug 05, 2026

Target

$330.00

Current

$368.75

Performance

6.01%

Daniel Grosslight rated BIO as Neutral on Aug 05, 2026, setting a price target of 330. Despite the Hold call, shares climbed 6.01% to 368.75, revealing unexpected momentum.

IDXX

Hold

Aug 05, 2026

Target

$670.00

Current

$506.53

Performance

-13.38%

On Aug 05, 2026, IDXX was given a Neutral rating by Daniel Grosslight, with a target price of 670. The rating provided protection from downside risk as the stock fell to 506.53.

HSIC

Buy

Aug 05, 2026

Target

$112.00

Current

$87.30

Performance

-2.56%

HSIC received a Buy rating from Daniel Grosslight on Aug 05, 2026, aiming for 112. Price action was muted, as shares hovered around 87.3 despite the bullish outlook.

TDOC

Hold

Aug 03, 2026

Target

$7.50

Current

$6.09

Performance

-8.83%

On Aug 03, 2026, Daniel Grosslight published a Neutral outlook on TDOC, with a target of 7.5. Weakness in the stock, now at 6.09, supported the conservative rating.

ACH

Buy

Jul 24, 2026

Target

$4.50

Current

$1.08

Performance

-65.61%

Daniel Grosslight on Jul 24, 2026 assigned ACH a Buy rating, with a price target of 4.5. The call has struggled to gain traction, with shares losing 65.61%.

MCK

Buy

Jul 24, 2026

Target

$1000.00

Current

$880.86

Performance

4.75%

On Jul 24, 2026, Daniel Grosslight reaffirmed MCK with a Buy rating, targeting 1000. Market indecision has kept the 1000 target in a holding pattern.

CAH

Buy

Jul 24, 2026

Target

$265.00

Current

$236.02

Performance

3.50%

CAH was rated Buy by Daniel Grosslight on Jul 24, 2026, with a price objective of 265. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

EVH

Hold

Jul 23, 2026

Target

$6.75

Current

$4.17

Performance

-10.13%

On Jul 23, 2026, Daniel Grosslight initiated coverage on EVH with a Neutral rating and target of 6.75. The rating matched the stock’s inability to hold above 4.17.

HIMS

Hold

Jul 23, 2026

Target

$35.00

Current

$27.44

Performance

-16.19%

Daniel Grosslight issued a Neutral recommendation for HIMS on Jul 23, 2026, price target set at 35. Market action validated the conservative Hold outlook with shares at 27.44.

AGL

Sell

Jul 23, 2026

Target

$105.00

Current

$92.60

Performance

-7.65%

On Jul 23, 2026, AGL was evaluated by Daniel Grosslight, who gave a Sell rating and target of 105. The recommendation was proven wrong by upward action toward 105.

GMRS

Buy

Jun 08, 2026

Target

$17.00

Current

$12.47

Performance

17.86%

Daniel Grosslight rated GMRS as Buy on Jun 08, 2026, setting a price target of 17. The call has proven timely, with shares rising 17.86% toward the price target of 17.

PHR

Hold

May 28, 2026

Target

$12.00

Current

$10.17

Performance

7.62%

On May 28, 2026, PHR was given a Neutral rating by Daniel Grosslight, with a target price of 12. The stock rallied from 10.17 to 10.17 after the Hold rating, surprising to the upside.

ZTS

Buy

May 18, 2026

Target

$112.00

Current

$72.89

Performance

-6.21%

ZTS received a Buy rating from Daniel Grosslight on May 18, 2026, aiming for 112. The rating hasn’t played out as hoped, with the stock trading 6.21% below expectations.

PAHC

Hold

May 14, 2026

Target

$44.00

Current

$36.58

Performance

1.19%

On May 14, 2026, Daniel Grosslight published a Neutral outlook on PAHC, with a target of 44. Sideways action left the Hold view intact, with no major move since 36.58.

GDRX

Buy

May 14, 2026

Target

$4.00

Current

$3.35

Performance

34.54%

Daniel Grosslight on May 14, 2026 assigned GDRX a Buy rating, with a price target of 4. The Buy call aligned well with market performance, producing a gain of 34.54%.

ELAN

Buy

May 07, 2026

Target

$31.00

Current

$22.86

Performance

-4.79%

On May 07, 2026, Daniel Grosslight reaffirmed ELAN with a Buy rating, targeting 31. Market indecision has kept the 31 target in a holding pattern.

COR

Buy

May 07, 2026

Target

$355.00

Current

$320.95

Performance

25.54%

COR was rated Buy by Daniel Grosslight on May 07, 2026, with a price objective of 355. A bullish response from the market helped close the gap of 34.05 to the target.

WAY

Buy

May 05, 2026

Target

$30.00

Current

$23.06

Performance

11.83%

On May 05, 2026, Daniel Grosslight initiated coverage on WAY with a Buy rating and target of 30. The stock’s climb of 11.83% since the call highlights the foresight in the rating.

ALGN

Buy

Apr 15, 2026

Target

$240.00

Current

$150.72

Performance

—

Daniel Grosslight issued a Buy recommendation for ALGN on Apr 15, 2026, price target set at 240. The target of 240 remains in play, though confirmation will depend on future moves.

XRAY

Sell

Apr 15, 2026

Target

$10.00

Current

$10.50

Performance

—

On Apr 15, 2026, XRAY was evaluated by Daniel Grosslight, who gave a Sell rating and target of 10. The Sell recommendation has not been clearly validated with shares unchanged at 10.5.

NVST

Hold

Apr 15, 2026

Target

$29.00

Current

$25.87

Performance

—

Daniel Grosslight rated NVST as Neutral on Apr 15, 2026, setting a price target of 29. The Hold stance appears justified, as shares hovered around 25.87 with a % move.

HCAT

Hold

Mar 13, 2026

Target

$1.75

Current

$1.73

Performance

31.06%

On Mar 13, 2026, HCAT was given a Neutral rating by Daniel Grosslight, with a target price of 1.75. The stock rallied from 1.73 to 1.73 after the Hold rating, surprising to the upside.

PRVA

Buy

Mar 03, 2026

Target

$34.00

Current

$20.37

Performance

-14.30%

PRVA received a Buy rating from Daniel Grosslight on Mar 03, 2026, aiming for 34. The rating hasn’t played out as hoped, with the stock trading 14.30% below expectations.

CTEV

Buy

Feb 25, 2026

Target

$63.00

Current

$36.74

Performance

147.91%

On Feb 25, 2026, Daniel Grosslight published a Buy outlook on CTEV, with a target of 63. Shares gained 147.91%, underscoring the accuracy of the bullish outlook toward 63.

OMI

Buy

Aug 12, 2025

Target

$7.00

Current

$2.68

Performance

-51.01%

Daniel Grosslight on Aug 12, 2025 assigned OMI a Buy rating, with a price target of 7. The call has struggled to gain traction, with shares losing 51.01%.

MPLN

Hold

Jan 10, 2025

Target

$12.50

Current

$23.15

Performance

81.85%

On Jan 10, 2025, Daniel Grosslight reaffirmed MPLN with a Neutral rating, targeting 12.5. Market strength beyond 23.15 went further than the conservative outlook suggested.

Frequency Asked Questions

Who is Daniel Grosslight?

Daniel Grosslight is an analyst from Citigroup specializing in the Healthcare sector.

What is Daniel Grosslight's success rate?

Daniel Grosslight currently has a success rate of +88.69%.

How many ratings has Daniel Grosslight issued?

Daniel Grosslight has issued 63 stock ratings so far.

What is the average return of Daniel Grosslight's calls?

Their stock ratings have generated an average return of +32.51%.

What is Daniel Grosslight's ranking?

Daniel Grosslight is ranked #677 out of 4771 analysts.

What types of ratings does Daniel Grosslight give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Daniel Grosslight?

You can follow Daniel Grosslight by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Daniel Grosslight?

Their latest rating was a Hold on BIO issued on 2026-08-05.